SOPA:NASDAQSociety Pass Incorporated Analysis
Data as of 2026-07-03 - not real-time
$0.08
Latest Price
9/10Risk
Risk Level: High
Executive Summary
Society Pass Inc (SOPA) is trading at a deep discount of $0.076, well below its 52‑week high of $6.28 and its analyst target of $21.25, reflecting extreme market pessimism. Technical indicators show a bearish price position under the 20‑day (0.046), 50‑day (0.209) and 200‑day (1.249) SMAs, a low RSI of 28.4 indicating oversold conditions, and a MACD histogram that has turned mildly positive, suggesting limited short‑term upside. Fundamentally, the company posted a -17.6% revenue decline, negative operating and profit margins (-3.80% and -1.46% respectively), and a massive cash burn with operating cash flow of -$18.9 M, raising doubts about near‑term survivability. The balance sheet is strained: a debt‑to‑equity ratio of 7.23 and a recent Chapter 11 filing underscore significant financial distress. Despite a theoretical upside of >27,000% based on price‑to‑target, the combination of high volatility (342% 30‑day), elevated beta (1.74), decreasing volume, and bankruptcy risk makes the stock exceptionally speculative.
Investors should weigh the stark contrast between the paper‑thin valuation metrics (PB 0.033, PS 0.135) and the real‑world challenges of restructuring, cross‑border regulatory exposure, and liquidity constraints before considering any position.
Investors should weigh the stark contrast between the paper‑thin valuation metrics (PB 0.033, PS 0.135) and the real‑world challenges of restructuring, cross‑border regulatory exposure, and liquidity constraints before considering any position.
Market Outlook
Short Term
< 1 yearCautious
Model confidence: 9/10
Key Factors
- Chapter 11 bankruptcy filing
- Negative cash flow and operating losses
- Bearish technical positioning below all major SMAs
Medium Term
1–3 yearsCautious
Model confidence: 8/10
Key Factors
- Uncertainty around restructuring outcome
- High beta and volatility
- Continued revenue decline and negative margins
Long Term
> 3 yearsNeutral
Model confidence: 6/10
Key Factors
- Potential upside if reorganization succeeds
- Extremely low price relative to book value
- Market sentiment extreme greed may drive speculative interest
Key Metrics & Analysis
Financial Health
Revenue Growth-17.60%
Profit Margin-146.00%
P/E Ratio-0.4
ROE-153.37%
ROA-25.95%
Debt/Equity7.22
P/B Ratio0.0
Op. Cash Flow$-18869904
Free Cash Flow$-8043035
Industry P/E16.7
Technical Analysis
TrendBearish
RSI28.4
Support$0.02
Resistance$0.08
MA 20$0.05
MA 50$0.21
MA 200$1.25
MACDBullish
VolumeDecreasing
Fear & Greed Index92.59
Valuation
Target Price$21.25
Upside/Downside27860.53%
GradeUndervalued
TypeValue
Risk Assessment
Beta1.74
Volatility342.31%
Sector RiskMedium
Reg. RiskHigh
Geo RiskHigh
Currency RiskMedium
Liquidity RiskHigh
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.